Clinical Trial Update: Sintilimab and Linperlisib Combination Treatment in Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study evaluating the combination of sintilimab and linperlisib for relapsed or refractory extranodal natural killer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Natural Killer T-cell Lymphoma

Drugs mentioned

• Linperlisib (linperlisib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Extranodal Natural Killer/T Cell Lymphoma | Phase 1 | Status: RECRUITING